Zepbound® (tirzepatide)

​

Tirzepatide

Tirzepatide is a relatively new medication initially developed for type 2 diabetes but has shown significant weight loss benefits. It works by activating both GLP-1 and GIP receptors, making it unique compared to semaglutide, which only targets GLP-1.

​

How Tirzepatide Helps with Weight Loss

​

• Dual Hormone Action (GLP-1 & GIP)

• GLP-1: Reduces appetite, slows digestion, and regulates blood sugar.

• GIP: Enhances the body's ability to burn fat and improve insulin sensitivity.

• Greater Weight Loss Potential: Clinical trials suggest it may lead to higher weight loss than semaglutide.

​

​Effectiveness

• SURMOUNT Trials (Clinical Studies)

  • Patients lost an average of 15-22% of their body weight over 72 weeks.

  • Outperformed semaglutide, which led to ~15% weight loss.

​

Dosage and Administration

• Typically starts at 2.5 mg once a week, gradually increasing to 15 mg weekly (for weight loss).

• Administered as a subcutaneous injection in the stomach, thigh, or upper arm.

​

Side Effects

• Common: Nausea, vomiting, diarrhea, constipation, bloating.

• Serious: Pancreatitis, gallbladder issues, kidney concerns, and thyroid tumors (black box warning).

• Tolerability: Some patients report fewer side effects compared to semaglutide.

​

Who Should Avoid Tirzepatide?

• Individuals with a history of medullary thyroid cancer (MTC) or MEN2.

• Those with severe gastrointestinal conditions.

• Pregnant or breastfeeding women.

​

Cost and Availability

• Expensive: ~$1,000+ per month without insurance.

• Insurance: Some plans cover Mounjaro for diabetes; Zepbound for weight loss may require prior authorization.

• Savings Programs: Eli Lilly offers a savings card for eligible patients with insurance, as well as lower price for self-pay patients (cash pay).

​

Semaglutide vs. Tirzepatide: Which Is Better for Weight Loss?

​​

​​​​​​​

​